Shares of Establishment Labs Holdings Inc. (ESTA) jumped more than 21% in pre-market trading on Friday, reaching $50.22, following the U.S. Food and Drug Administration's approval of its Motiva breast implants.
According to a company statement, the Motiva implants, which include the Motiva SmoothSilk Ergonomix and Motiva SmoothSilk Round models, are engineered to improve biocompatibility and minimize inflammation.
On Thursday, Establishment Labs' stock closed at $41.19, marking a 3.25% increase. Over the past year, the stock has fluctuated between $16.96 and $60.12.
